Abstracts

TRANSMISSION, VARIATION, AND EVOLUTION OF IN UTERO TRANSMITTED HIV-1

HIV-1 can be transmitted from infected mothers to their fetuses during pregnancy. However, the transmission timing, viral diversity, and selection pressure on fetal viruses during pregnancy is poorly understood. A better understanding of transmission mechanisms will be key to further reduce the mother-to-child-transmission (MTCT) rate. Viral RNA was extracted from plasma of 12 mothers (at…

CABOTEGRAVIR PHARMACOKINETIC TAIL IN PREGNANCY AND NEONATAL OUTCOMES

Cabotegravir (CAB) is a long-acting (LA) HIV integrase inhibitor in Phase 3 development for HIV treatment in combination with rilpivirine LA, and as monotherapy for HIV prevention. Injectable CAB LA, given monthly or every 2 months, maintains plasma concentrations that may persist for a year or longer following discontinuation. Nonclinical reproductive toxicology studies of CAB…

COST-EFFECTIVENESS OF BROADLY NEUTRALIZING ANTIBODIES FOR INFANT HIV PROPHYLAXIS

Injectable infant prophylaxis with a broadly neutralizing antibody (bNAb) could help overcome gaps in the prevention of vertical HIV transmission cascade by providing long-acting protection from postnatal transmission, but there are few insights into the potential cost-effectiveness of this strategy. Using the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-Pediatric model, we simulated children known to be…

RILPIVIRINE IN HIV-1–INFECTED WOMEN INITIATING PREGNANCY: TO SWITCH OR NOT TO SWITCH?

Data about safety and efficacy of rilpivirine (RPV) during pregnancy remain scarce. Because RPV plasma concentrations are reduced during 2nd and 3rd trimesters of pregnancy and viral breakthroughs were observed, French guidelines recommend switching to RPV-free cART during pregnancy. This study aimed to describe the characteristics of women initiating pregnancy while on RPV and to…